Pharmacogenetics of selective serotonin reuptake inhibitor response: A 6-month follow-up

Pharmacogenetics

Volumn 14, Issue 9, 2004, Pages 607-613

  Serretti, Alessandro ^a,b   Zanardi, Raffaella ^a   Franchini, Linda ^a   Artioli, Paola ^a   Dotoli, Danilo ^a   Pirovano, Adele ^a   Smeraldi, Enrico ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Follow up; Polymorphism; Recurrent major depression; SSRI

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; FLUVOXAMINE; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN HYDROXYLASE;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE;

ADULT; ALLELES; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DNA; EXONS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; IMIDAZOLES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MONOAMINE OXIDASE; NERVE TISSUE PROTEINS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TRANS-ACTIVATORS; TREATMENT OUTCOME;

EID: 4644332454     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200409000-00005     Document Type: Article

References (61)

1. O'Reilly RL, Bogue L, Singh SM. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry 1994; 36:467-471.
2. Orsini A. Antidepressant responses and segregation analyses in affective families. in: Anxious Depression: assessment and treatment. Racagni G, Smeraldi E (editors). New York: Raven Press; 1987.
3. Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3:508-511.
4. Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol 2000; 20:105-107.
5. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23:587-590.
6. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001; 50:323-330.
7. Arias B, Catalan R, Gasto C, Imaz ML, Gutierrez B, Pintor L, Fananas L. Genetic variability in the promoter region of the serotonin transporter gene is associated with clinical remission of major depression after long term treatment with citalopram. World Federation of societies of Biological Psychiatry. Berlin: Germany; 2001, pp. 9S.
8. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7:1115-1119.
9. Cusin C, Serretti A, Lattuada E, Lilli R, Lorenzi C, Mandelli L, et al. Influence of 5-HTTLPR and TPH Variants on illness time course in mood disorders. J Psychiatr Res 2001; 35:217-223.
10. Rousseva A, Henry C, Van Den Bulke D, Fournier G, Laplanche JL, Leboyer M, et al. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenom J 2003; 3:101-104.
11. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder. Arch Gen Psychiatry 2001; 58:539-544.
12. Artioli P, Serretti A, Lattuada E, Lorenzi C, Lilli R, Smeraldi E. Clinical and genetic features of antidepressant induced mania in bipolar disorder. Xth World Congress of Psychiatric Genetics. Brussels; 2002. p. 755.
13. Smeraldi E, Benedetti F, Zanardi R. Serotonin transporter promoter genotype and illness recurrence in mood disorders. Eur Neuropsychopharmacol 2002; 12:73-75.
14. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6:586-592.
15. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001; 11:375-380.
16. Peters EJ, Stager SL, McGrath PJ, Knowles JA, Hamilton SP. Pharmacogenomic analysis of five serotonergic pathway genes in antidepressant response. II Annual Pharmacogenetics in Psychiatry Meeting 2003. New York.
17. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11:215-219.
18. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, et al. Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1279-1283.
19. Franchini L, Gasperini M, Smeraldi E. A 24-month follow-up study of unipolar subjects: a comparison between lithium and fluvoxamine. J Affect Disord 1994; 32:225-231.
20. Franchini L, Zanardi R, Gasperini M, Perez J, Smeraldi E. Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. J Affect Disord 1996; 38:67-69.
21. Reynolds CF, Frank E, Perel JM, Imber SD, Comes C, Miller MD, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression - a randomized controlled trial in patients older than 59 years. JAMA 1999; 281:39-45.
22. Kupfer DJ, Frank E, Perel JM, Comes C, Mallinger AG, Thase ME, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49:769-773.
23. Hirschfeld RM. Clinical importance of long-term antidepressant treatment. Br J Psychiatry Suppl 2001; 42:S4-S8.
24. Pincus HA, Pettit AR. The societal costs of chronic major depression. J Clin Psychiatry 2001; 62(suppl 6):5-9.
25. Bauwens F, Tracj A, Pardoen D, Vander Elst M, Mendlewicz J. Social adjustment of remitted Bipolar and Unipolar out-patients. A comparison with age-and sex-matched controls. Br J Psychiatry 1991; 159: 239-244.
26. Montgomery SA, Doogan DP, Burnside R. The influence of different relapse criteria on the assessment of long-term efficacy of sertraline. Int Clin Psychopharmacol 1991; 6(suppl 2):37-46.
27. Lin EH, Katon WJ, VonKorff M, Russo JE, Simon GE, Bush TM, et al. Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med 1998; 7:443-449.
28. Keller MB, Lavori PW, Lewis CE, Klerman GL. Predictors of relapse in major depressive disorder. JAMA 1983; 250:3299-3304.
29. Lowrey PL, Takahashi JS. Genetics of the mammalian circadian system: Photic entrainment, circadian pacemaker mechanisms, and posttranslational regulation. Annu Rev Genet 2000; 34:533-562.
30. Reppert S, Weaver D. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol 2001; 63:647-676.
31. King DP, Vitaterna MH, Chang AM, Dove WF, Pinto LH, Turek FW, Takahashi JS. The mouse Clock mutation behaves as a antimorph and maps within the W19H deletion, distal of Kit. Genetics 1997; 146:1049-1060.
32. Steeves TD, King DP, Zhao Y, Sangoram AM, Du F, Bowcock AM, et al. Molecular cloning and characterization of the human clock gene: mexpression in the suprachiasmatic nuclei. Genomics 1999; 57:198-200.
33. Abe H, Honma S, Namihira M, Tanahashi Y, Ikeda M, Honma K. Circadian rhythm and light responsiveness of BMAL1 expression, a partner of mammalian clock gene Clock, in the suprachiasmatic nucleus of rats. Neurosci Lett 1998; 258:93-96.
34. Mignone F, Gissi C, Liuni S, Pesole G. Untranslated regions of mRNAs. Genome Biol 2002;3:REVIEWS0004.
35. Benedetti F, Serretti A, Colombo C, Barbini B, Lorenzi C, Campori E, Smeraldi E. Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet 2003; 123B:23-26.
36. Serretti A, Benedetti F, Mandelli L, Lorenzi C, Pirovano A, Colombo C, Smeraldi E. Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. Am J Med Genet 2003; 121B:39-43.
37. Serretti A, Cusin C, Benedetti F, Mandelli L, Pirovano A, Zanardi R, et al. Insomnia improvement during antidepressant treatment is associated with CLOCK gene polymorphism. Am J Med Genet; in press.
38. Hamilton M. Development of a rating scale for primary depressive illness. Br J Social Clin Psychol 1967; 6:278-296.
39. Bech P, Malt U, Dencker S, Ahlfors U, Elgen K, Lewander T, et al. Scales for assessment of diagnosis and severity of mental disorders. Acta Psychiatr Scand 1993; 87(suppl 372):37-40.
40. Sobin CA, Sackeim H. Psychomotor symptoms of depression. Am J Psychiatry 1997; 154:4-17.
41. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157:1-45.
42. Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996; 153:414-416.
43. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48:851-855.
44. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 151:1-36.
45. Lucca A, Lucini V, Catalano M, Alfano M, Smeraldi E. Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor. Neuropsychobiology 1994; 29:108-111.
46. Lahiri DK, Nurnberger JIJ. A rapid non-enzimatic method for the preparation of HMW DNA from blood for RFLP studies. Nucl Acid Res 1991; 19:5444.
47. Serretti A, Lorenzi C, Lilli R, Mandelli L, Pirovano A, Smeraldi E. Pharmacogenetics of lithium prophylaxis in mood disorders: Analysis of COMT, MAO-A, and Gbeta3 variants. Am J Med Genet 2002; 114: 370-379.
48. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998; 103:273-279.
49. Serretti A, Cusin C, Lorenzi C, Lattuada E, Lilli R, Smeraldi E. Serotonin-2a receptor gene is not associated with symptomatology of schizophrenia. Am J Med Genet 2000; 96:84-87.
50. Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D, et al. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 1999; 8: 621-624.
51. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1988.
52. Pintor L, Gasto C, Navarro V, Torres X, Fananas L. Relapse of major depression after complete and partial remission during a 2-year follow-up. J Affect Disord 2003; 73:237-244.
53. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998; 55: 1128-1132.
54. O'Leary D, Costello F, Gormley N, Webb M. Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients. J Affect Disord 2000; 57:159-171.
55. Lewinsohn PM, Zeiss AM, Duncan EM. Probability of relapse after recovery from an episode of depression. J Abnorm Psychol 1989; 98:107-116.
56. Birkenhager TK, Renes JW, Pluijms EM. One-year follow-up after successful ECT: a naturalistic study in depressed inpatients. J Clin Psychiatry 2004; 65:87-91.
57. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 1992; 149:795-800.
58. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea T, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157:229-233.
59. Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 1984; 41:782-786.
60. Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry 1987; 44:259-264.
61. Blazer DG. Severe episode of depression in late life - the long road to recovery. Am J Psychiatry 1997; 153:1620-1623.